NAD+ Research 2026: The Focus Shifts From Supplementation to Stopping the Leak

NAD+ (nicotinamide adenine dinucleotide) has cemented its position as one of the central molecules in longevity science, and the research continues to deepen in 2026. A systematic review published in Ageing Research Reviews analyzed the cumulative evidence from both preclinical and clinical studies, finding that NAD+ precursor supplementation — particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — consistently improves muscle function, insulin sensitivity, and cardiovascular markers in older adults in controlled trials. The review also highlighted benefits in rare diseases characterized by premature aging and DNA damage, where NAD supplementation demonstrably improved DNA repair capacity and mitochondrial function.

However, the frontier of NAD+ research in 2026 is moving beyond simply topping off declining levels to targeting the enzymes that consume NAD+ at elevated rates as we age. The key culprits — CD38, PARPs (poly ADP-ribose polymerases activated by DNA damage), and dysregulated NAMPT — accelerate the decline of NAD+ pools in aged tissue. Inhibiting CD38 with compounds like apigenin or specialized preclinical agents while simultaneously boosting NAD+ precursor intake appears to produce additive effects in animal models, a strategy now entering early human trials.

Delivery method is also under active investigation. A January 2026 analysis comparing NAD+ delivery approaches found that intravenous infusions remain the most bioavailable option for acute restoration of NAD+ levels, while subcutaneous NMN injections represent a practical middle ground. As telehealth platforms expand access to these protocols, the conversation is shifting from boutique longevity clinics to broader preventive medicine — a trend reflected in a reported 300% increase in online searches for NAD+ therapy costs over the past year.